HER2阳性转移性乳腺癌治疗年度进展

Annual progress of HER2 positive metastatic breast cancer

乳腺癌是我国女性发病率最高的恶性肿瘤,其中HER2阳性转移性乳腺癌在晚期乳腺癌占比为25%~30%。HER2阳性乳腺癌患者预后差,如何提高HER2阳性转移性乳腺癌的治疗效果,包括优化靶向治疗、化疗药物的选择、后线治疗的策略等具有重要的临床意义。本文基于2017年各大乳腺癌会议,针对HER2阳性转移性乳腺癌在临床中的常见问题,阐述HER2阳性转移性乳腺癌治疗策略的新进展。

Breast cancer is one of the most common malignant disease in China.HER2 positive meta-static breast cancer accounted for 25%to 30%.The prognosis of HER2 positive metastatic breast cancer is poor,how to improve the therapeutic effect of HER2 positive metastatic breast cancer havevitalclinical-significance,including optimize targeted therapy,selection of chemotherapy and strategy beyond first-line therapy.This article based on the 2017 breast cancer conference and reviewed thelatestprogress of HER2 positive metastatic breast cancer.